Please select the option that best describes you:
In the absence of an available clinical trial, would you favor regorafenib immediately post-sorafenib or nivolumab in patients with HCC?
Regorafenib has been approved for patients with advanced HCC post-sorafenib, but the benefits are slight and toxicity substantial. Nivolumab has encouraging early data, with much more manageable toxicity.
Answer from: Medical Oncologist at Academic Institution
At this point in time, given the continued encouraging data regarding the efficacy of immune checkpoint blockade in HCC coupled with the substantially lower toxicity when compared to regorafenib, I would choose off-label nivolumab in this particular scenario.
Sign in or Register to read more